A process for purifying eslicarbazepine acetate is provided The crystalline particles of eslicarbazepine acetate having a median particle size between 5 μm and 20 μm and a specific surface area of from 0.1 m2/g to 10 m2/g as measured by B.E.T. method are obtained Eslicarbazepine acetate having purity greater than 99.0% as measured by high performance liquid chromatography and a pharmaceutical composition containing the same are also provided.La présente invention concerne la purification et la taille particulaire de lacétate deslicarbazépine. Linvention concerne également les caractéristiques physiques de lacétate deslicarbazépine à létat solide, et des compositions pharmaceutiques le contenant.
